immatics biotechnologies GmbH (4A3) — Financial Flexibility Index

Latest as of December 2025: -0.74x

immatics biotechnologies GmbH (4A3) has a Financial Flexibility Index of -0.74x as of December 2025. Free cash flow of €-57.64 Million (operating CF €-58.66 Million minus capex €1.03 Million) represents -1% of total liabilities (€78.24 Million). Check immatics biotechnologies GmbH PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Financial Flexibility Index

-0.74x
Free Cash Flow / Total Liabilities

Free Cash Flow

€-57.64 Million
Operating CF − Capex

Total Liabilities

€78.24 Million
EUR

Capital Expenditures

€1.03 Million
EUR

immatics biotechnologies GmbH Financial Flexibility Index (2019–2025)

Historical Financial Flexibility Index trend for immatics biotechnologies GmbH across 7 annual periods. See immatics biotechnologies GmbH (4A3) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Annual Financial Flexibility Index for immatics biotechnologies GmbH (2019–2025)

Year-by-year free cash flow to debt coverage for immatics biotechnologies GmbH. For the full company profile including market capitalisation, see immatics biotechnologies GmbH (4A3) total market value.

Year Flexibility Index Free Cash Flow (EUR) Operating CF Total Liabilities YoY Change
2025 -2.17x €-169.82 Million €-176.63 Million €78.24 Million ▼ -86.0%
2024 -1.17x €-141.55 Million €-158.03 Million €121.30 Million ▼ -775.9%
2023 0.17x €49.19 Million €18.23 Million €284.88 Million ▼ -68.3%
2022 0.54x €105.87 Million €100.13 Million €194.66 Million ▼ -22.2%
2021 0.70x €105.24 Million €100.13 Million €150.58 Million ▼ -2.3%
2020 0.72x €107.55 Million €100.13 Million €150.39 Million ▲ +71.3%
2019 0.42x €73.11 Million €70.97 Million €175.11 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities